Azopt · DIN 02238873 · 1% · Oph suspension
Limited Use, Reason for Use code 171, 172, 387 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171
As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 172
As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 387
For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Azopt · DIN 02238873
Manufacturer: Novartis Pharma Canada Inc.; listing date 2000-01-17
Health Canada: Marketed since 2018-03-14 · brand AZOPT · ATC S01EC04 BRINZOLAMIDE · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Azopt: Formulary list price $3.56 per unit (the source does not state the unit; exact figure $3.5560). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238873)
Source record
DIN 02238873: Azopt
Raw flags: sec12=Y, sec3=Y
Item: 523600096; group id 616; item number 1583; lccId 00083; manufacturer id NOV
Source form: Oph Susp; strength: 1%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.5560; ministry $3.5560
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238873
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62313
Shortage status: not checked (no credentials)